Lupin Pharmaceuticals, Inc. Sustainability Profile
Lupin Pharmaceuticals, Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States. Founded in 1968, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Specialising in generic and branded medications, Lupin focuses on therapeutic areas such as cardiovascular, diabetes, and central nervous system disorders. With a commitment to innovation, Lupin has achieved significant milestones, including numerous FDA approvals and a robust pipeline of products. Their core offerings, which include high-quality generics and specialty pharmaceuticals, are distinguished by their efficacy and affordability. As a leading manufacturer, Lupin Pharmaceuticals is recognised for its market position, consistently ranking among the top generic drug producers in the US, reflecting its dedication to improving patient outcomes worldwide.
DitchCarbon Score
How does Lupin Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lupin Pharmaceuticals, Inc.'s score of 63 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lupin Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Lupin Limited, which may influence its climate commitments and emissions reporting. As part of its climate strategy, Lupin Pharmaceuticals inherits reduction initiatives and targets from its parent company, Lupin Limited. However, there are no documented reduction targets or specific climate pledges available at this time. The absence of emissions data and reduction targets suggests that Lupin Pharmaceuticals is still in the process of establishing its own climate commitments or may rely on the broader corporate strategies of Lupin Limited. Given the lack of specific emissions data, it is essential for Lupin Pharmaceuticals to develop and communicate clear climate commitments to align with industry standards and expectations. This would not only enhance transparency but also contribute to global efforts in reducing carbon emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 103,887,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 371,883,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 680,968,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Lupin Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Lupin Pharmaceuticals, Inc.'s Location?
Lupin Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Lupin Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
